Humana

Clarifai Hires Chris Kent as SVP Marketing

Retrieved on: 
Tuesday, February 27, 2024

WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Clarifai, a global leader in AI development and a pioneer of the full-stack AI platform, announced today that Chris Kent will join as SVP of Marketing as Clarifai expands into more enterprises, enabling them to build and operationalize AI faster.

Key Points: 
  • WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Clarifai , a global leader in AI development and a pioneer of the full-stack AI platform, announced today that Chris Kent will join as SVP of Marketing as Clarifai expands into more enterprises, enabling them to build and operationalize AI faster.
  • Kent brings decades of marketing and category creation experience to Clarifai, which has spent 10 years perfecting its capabilities to enable teams to build AI in minutes, not months, and unlock value instantly.
  • Kent was formerly VP of Product, Solutions, Partner and Customer Marketing for Cohesity and VP of Product Marketing for HashiCorp, where he helped grow the company to over $300 million ARR and a successful IPO.
  • "Clarifai is perfectly timed to establish itself as a leader in this category given the need of companies to quickly operationalize AI and stay ahead of competitors," said Kent.

RhythmX AI and Sentara Health Announce Groundbreaking Collaboration to Forge the Future of Primary Care with Predictive and Generative AI-driven Copilot for Clinicians

Retrieved on: 
Thursday, February 22, 2024

PALO ALTO, Calif., Feb. 22, 2024 /PRNewswire/ -- RhythmX AI, a generative AI-native company driving revolutionary physician intelligence for whole-person care through cutting-edge predictive and generative AI, announced a strategic partnership with Virginia-based Sentara Health, one of the top 20 largest not-for-profit integrated health care delivery systems in the country.

Key Points: 
  • "We are going after a big, shared vision that truly reshapes healthcare," said RhythmX AI CEO Deepthi Bathina
    Together, RhythmX AI and Sentara are building the next generation of hyper-personalized primary care for clinicians and patients.
  • With RhythmX AI's predictive and generative AI platform, Sentara primary care clinicians will have access to next-best clinical actions surfaced directly from the relevant clinical and payor guidelines, earlier disease detection, underlying EMR data analyses, and documentation support.
  • "RhythmX AI and Sentara are truly embarking on the next evolution in primary care delivery together," said Michael Kalishman, Chief Venture and Innovation Officer at Sentara.
  • "With our shared vision for the future, Sentara is excited to partner its leading clinician expertise and primary care redesign approach with RhythmX AI's predictive and generative AI platform.

Clarifai Hires Amith Nair as President and COO

Retrieved on: 
Tuesday, February 20, 2024

WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- Clarifai, a global leader in AI development and a pioneer of the full-stack AI platform, today announced that Amith Nair will join as President and COO, guiding enterprise customers through the shift from AI exploration to building AI faster and realizing meaningful value.

Key Points: 
  • "We're thrilled to add Amith to our team and the timing is perfect," said Matt Zeiler, Ph.D., Founder and CEO of Clarifai.
  • Clarifai was built to deliver and Amith will ensure we are best supporting developers and teams in running AI at scale in minutes, not months."
  • Prior to Clarifai, Nair served in senior leadership positions in product, operations and marketing strategy at Cohesity, HashiCorp and Microsoft.
  • "Adding Amith to Clarifai as COO is a game changer!

Clarifai Hires Amith Nair as President and COO

Retrieved on: 
Tuesday, February 20, 2024

WASHINGTON, Feb. 20, 2024 /PRNewswire/ -- Clarifai, a global leader in AI development and a pioneer of the full-stack AI platform, today announced that Amith Nair will join as President and COO, guiding enterprise customers through the shift from AI exploration to building AI faster and realizing meaningful value.

Key Points: 
  • "We're thrilled to add Amith to our team and the timing is perfect," said Matt Zeiler, Ph.D., Founder and CEO of Clarifai.
  • Clarifai was built to deliver and Amith will ensure we are best supporting developers and teams in running AI at scale in minutes, not months."
  • Prior to Clarifai, Nair served in senior leadership positions in product, operations and marketing strategy at Cohesity, HashiCorp and Microsoft.
  • "Adding Amith to Clarifai as COO is a game changer!

Humana Board Declares Payment of Quarterly Dividend to Stockholders

Retrieved on: 
Thursday, February 15, 2024

Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.

Key Points: 

Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.

Glytec Announces Major Expansion of Executive Team to Drive Innovation and Growth

Retrieved on: 
Tuesday, January 30, 2024

WALTHAM, Mass., Jan. 30, 2024 /PRNewswire/ -- Glytec, the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, proudly announces the addition of key healthcare leaders to its executive team to continue to scale the company, grow its client base, and meet the needs of the growing healthcare industry and diabetes technology market. 

Key Points: 
  • I feel privileged to collaborate with this team of experts with an extensive track record of healthcare innovation, positive patient impact at scale, and a history of remarkable success," said Patrick Cua, CEO of Glytec.
  • [2]
    The market demand for Glucommander is surging, and these seasoned executives will bring invaluable experience and skills to drive and support continued growth.
  • McPherson's strategic financial leadership will play a crucial role in sustaining Glytec's growth trajectory and fortifying the foundation for continued innovation.
  • These healthcare leaders will join a broader, dynamic team that is set to drive groundbreaking advancements in diabetes technology, healthcare applications, and market impact.

Adam Beam named CEO of ImagineCare

Retrieved on: 
Wednesday, January 24, 2024

JACKSONVILLE, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ImagineCare , a joint venture between Spark Pediatrics and CareSource, announced the appointment of Adam Beam as CEO.

Key Points: 
  • JACKSONVILLE, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ImagineCare , a joint venture between Spark Pediatrics and CareSource, announced the appointment of Adam Beam as CEO.
  • In this role, Beam will oversee member growth, provider strategies and health plan performance.
  • "Collaborating with Adam has been an exceptional experience,” said Jeff Soffen, CEO of Spark Pediatrics and chair of the ImagineCare board.
  • "We are pleased to announce the appointment of Adam Beam to lead ImagineCare,” said Scott Markovich, executive vice president of markets and products for CareSource, and ImagineCare board member.

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Retrieved on: 
Thursday, January 18, 2024

Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.

Key Points: 
  • Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.
  • “We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
  • He is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine and a practicing cancer surgeon at Howard University Hospital.
  • Dr. Frederick earned a B.S., M.D., and completed his surgical residency training at Howard University Hospital.

Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests

Retrieved on: 
Wednesday, January 24, 2024

Tempus, a leader in artificial intelligence and precision medicine, today announced that the company has signed agreements for in-network provider status with Humana Inc.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced that the company has signed agreements for in-network provider status with Humana Inc.
  • Under the agreement, Humana’s over 13 million members will have improved access to Tempus’ portfolio of molecular profiling tests in accordance with their medical policies, expanding precision oncology care throughout the country.
  • In-network coverage of Tempus’ assays will support broader access to precision cancer care and may lead to lower out-of-pocket costs for patients who receive any such testing in accordance with their individual plan.
  • “This is a big step in broadening access to the precision medicine solutions that should be available to all patients facing cancer,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus.

Humana Inc. Reschedules Fourth Quarter 2023 Earnings Call to Thursday, January 25, at 9:00 a.m. E.T.

Retrieved on: 
Thursday, January 18, 2024

Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2023 (4Q23), as well as prepared management remarks (in PDF format), on Thursday, January 25, 2024, at approximately 6:30 a.m. Eastern time.

Key Points: 
  • Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2023 (4Q23), as well as prepared management remarks (in PDF format), on Thursday, January 25, 2024, at approximately 6:30 a.m. Eastern time.
  • The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024.
  • The call was originally scheduled for Monday, February 5, but was rescheduled to provide a more timely update on the company’s performance and 2024 guidance.
  • The company’s 4Q23 earnings news release is expected to include financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP).